aTyr Pharma Inc. (LIFE)
Symbol Info
Listed Symbol LIFE
Name aTyr Pharma Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-16.08
Price Info
21 Day Moving Average $3.2270
21 Day EMA $3.387380
50 Day Moving Average $3.5145
50 Day EMA $3.715460
200 Day EMA $7.138880
200 Day Moving Average 6.089910
52 Week High $12.33
52 Week Low $2.76
52 Week Change $-62.571400
Alpha -0.074501
Beta 2.4623
Standard Deviation 0.220638
R2 0.158909
Periods 52
Share Information
10 Day Average Volume 56,815
20 Day Average Volume 44,965
30 Day Average Volume 56,732
50 Day Average Volume 120,259
Outstanding Shares 3,890,185
Float Shares 2,854,513
Percent Float 73.38%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 51
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 3,465,818
Institute Holdings Percent 42.300000
Institute Sold Previous 3 Months 480,137
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,035,672
Price Change
7 Day Price Change $0.5400000
7 Day Percent Change 15.93%
21 Day Price Change $0.8300002
21 Day Percent Change 26.77%
30 Day Price Change $1.0105000
30 Day Percent Change 34.61%
Month To Date Price Change $0.9900
Month To Date Percent 33.67%
90 Day Price Change $-0.9294
90 Day Percent Change -19.13%
Quarter To Date $-1.1996
Quarter To Date Percent -23.39%
180 Day Price Change $-2.622
180 Day Percent Change -40.02%
200 Day Price Change $-2.65
200 Day Percent Change -40.27%
Year To Date $-3.0098
Year To Date Percent -43.37%
Profile
Description aTyr Pharma Inc is a biotherapeutics company, engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology. It has discovered approximately 300 Physiocrines, a class of naturally occurring human proteins that it promotes homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state. The company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Business activity is primarily conducted through the United States.
Details
Issue Type CS
Market Cap $15,288,427
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 3,890,185
CEO Sanjay S. Shukla
Employees 42
Last Audit UQ
Classification
CIK 0001339970
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 3545 John Hopkins Court
Suite Number 250
San Diego, CA 92121
Website https://www.atyrpharma.com
Facisimile +1 858 731-8394
Telephone +1 858 731-8389
Email investorrelations@atyrpharma.com
Key Ratios
Profitability
EBIT Margin -25,700
EBITDA Margin -24,590.4
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $94,000
Revenue Per Share $0.0242
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $-14,660,231
Price To Sales 162.642850
Price To Free Cash -0.5
PE High Last 5 Years -
Price To Book 0.4
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 0.4
Financial Strength
Total Debt To Equity 0.5
Int Coverage -
Current Ratio 3.9
Leverage Ratio 1.6
Quick Ratio 3.8
Long Term Debt To Capital 0.19
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -44.08
Return On Equity -68.29
Return On Capital -45.84
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
LIFE
aTyr Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.